<DOC>
	<DOCNO>NCT00429559</DOCNO>
	<brief_summary>Topotecan gemcitabine drug globally register recurrent ovarian carcinoma . This trial determine maximum tolerate dose efficacy combination administer weekly patient platinum -resistant ovarian cancer .</brief_summary>
	<brief_title>Topotecan Combination With Gemcitabine Patients With Platinum-resistant Ovarian Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically cytologically confirm ovarian adenocarcinoma Patients receive frontline , platinum base chemotherapy regimen Patients progress whose best response recent platinumbased therapy less partial response classify platinumrefractory/resistant ovarian cancer . This category also include patient disease progression within six month complete recent platinumbased chemotherapy Patients least one bidimensionally measurable and/or evaluable ( unidimensionally measurable ) target lesion nonirradiated area , increase Ca 125 A &gt; = 4 week interval last chemotherapy regimen start study treatment Age &gt; 18 year old Performance status ( WHO ) 02 Life expectancy least three month Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , hemoglobin &gt; 9 gr/mm^3 ) Adequate liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2 mg/dl ) Informed consent Pregnant nursing Psychiatric illness social situation would preclude study compliance Other concurrent uncontrolled illness Other invasive malignancy within past 5 year except nonmelanoma skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Cancer ;</keyword>
	<keyword>Ovarian cancer ;</keyword>
	<keyword>Recurrent ovarian cancer platinum-resistant</keyword>
</DOC>